Overview of BridgeBio's Upcoming Participation
BridgeBio Pharma, Inc. (NASDAQ: BBIO), known for its innovative approach in biopharmaceuticals focused on genetic diseases, is gearing up for significant participation in a couple of prominent investor conferences this December. The company's management team will be present for crucial discussions and presentations that will shed light on their pipeline and strategic direction.
Fireside Chats Scheduled
During the month of December, BridgeBio Pharma will be featured in key investor engagements at the following conferences:
Piper Sandler Healthcare Conference
This noteworthy event will take place in New York, where executives from BridgeBio will participate in a fireside chat scheduled for December 2 at 10:30 AM EST. This will be an excellent opportunity for investors to gain first-hand insights into the company’s innovations and future plans.
EvercoreISI HealthCONx Conference
Shortly after the Piper Sandler event, BridgeBio will attend the EvercoreISI HealthCONx Conference in Miami. Their presentation is slated for December 3 at 3:00 PM EST, promising to further illuminate their commitment to advancing treatments for genetic conditions.
Accessing the Live Presentations
Investors and other interested parties can tune in to the live webcasts of these presentations by navigating to the 'Events and Presentations' page in the Investors section on BridgeBio’s official website. This feature will enable followers to stay informed directly from the source, ensuring they do not miss out on crucial updates regarding the firm’s projects and potential impacts.
BridgeBio Pharma's Commitment to Genetic Medicine
Founded in 2015, BridgeBio Pharma has quickly established itself as a leader in the biopharmaceutical industry by focusing on finding and delivering innovative treatments for patients suffering from genetic disorders. The company’s comprehensive pipeline includes numerous development programs that showcase its dedication to leveraging cutting-edge advances in genetic medicine.
Contacting BridgeBio for Inquiries
For those interested in reaching out to BridgeBio, the company’s media and investor relations contacts are available for inquiries. Bubba Murarka, Executive Vice President of Corporate Development, is the media contact, while Chinmay Shukla, Senior Vice President of Strategic Finance, serves as the investor contact. Both can provide further insights and updates about the company’s conference presentations and other initiatives.
Frequently Asked Questions
What are the dates and times for the BridgeBio conference presentations?
BridgeBio will present at the Piper Sandler Healthcare Conference on December 2 at 10:30 AM EST and at the EvercoreISI HealthCONx Conference on December 3 at 3:00 PM EST.
How can I access the live webcasts of BridgeBio's presentations?
Interested parties can access live webcasts by visiting the 'Events and Presentations' page in the Investors section of BridgeBio's official website.
What is the focus of BridgeBio Pharma?
BridgeBio Pharma specializes in developing treatments for patients diagnosed with genetic diseases, emphasizing innovative and transformative therapies.
Who are the key contacts at BridgeBio?
The media contact is Bubba Murarka, and the investor contact is Chinmay Shukla. Both are available for inquiries regarding the company’s activities.
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015 and has grown rapidly in the biopharmaceutical industry since its inception.
